Does low omega-3 status reduce inflammation-resolution capacity?

Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are not merely structural components of cell membranes but serve as essential precursors for the biochemical signals that actively terminate inflammation. A low omega-3 status creates a substrate deficit that hampers the body’s ability to transition from an inflammatory state to a resolved, homeostatic state.

Mechanistic basis for resolution

The resolution of inflammation is an active, highly orchestrated process rather than a passive "fading away." It requires a "lipid mediator class switch" where the body transitions from producing pro-inflammatory eicosanoids (like prostaglandins) to specialized pro-resolving mediators (SPMs).

• Substrate availability: EPA and DHA are the primary substrates for these SPMs. EPA is enzymatically converted into E-series resolvins (RvE1–RvE3), while DHA is the precursor for D-series resolvins (RvD1–RvD6), protectins (e.g., PD1), and maresins.
• Enzymatic pathways: This conversion is mediated by specific oxygenase enzymes, including 5-lipoxygenase (5-LOX), 15-LOX, and cyclooxygenase-2 (COX-2). Research shows that increasing omega-3 intake elevates levels of key intermediates like 18-HEPE and 17-HDHA, directly fueling the production of SPMs.

Impact on inflammation capacity

When omega-3 levels are low, the biosynthetic pathway for SPMs is restricted, which can lead to "non-resolving" inflammation.

• Cellular effects: SPMs function at nanomolar concentrations to reduce further neutrophil recruitment and enhance efferocytosis—the clearing of cellular debris by macrophages.
• Clinical correlations: Higher omega-3 status (measured via the Omega-3 Index) is associated with increased SPM levels and improved resolution in various conditions, including obesity and certain chronic inflammatory disorders. Without sufficient EPA and DHA, the inflammatory response may persist, contributing to chronic tissue damage.

Bottom line

The claim is strongly supported by science. Low omega-3 status directly impairs the synthesis of specialized pro-resolving mediators, thereby reducing the body's physiological capacity to actively terminate inflammation and prevent its progression into a chronic state.